Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro

Journal of Experimental and Clinical Cancer Research

Volumn 35, Issue 1, 2016, Pages

  Sun, Caixing ^a   Yu, Yang ^a   Wang, Lizhen ^a   Wu, Bin ^a   Xia, Liang ^a   Feng, Fang ^a   Ling, Zhiqiang ^a   Wang, Shihua ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Allograft; Angiogenesis; Glioblastoma; Metronomic; rCBV; RG3; TMZ; VEGF

Indexed keywords

CD34 ANTIGEN; GINSENOSIDE RG 3; PROTEIN BCL 2; TEMOZOLOMIDE; VASCULOTROPIN A; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DACARBAZINE; GINSENOSIDE;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BRAIN BLOOD VOLUME; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; S PHASE CELL CYCLE CHECKPOINT; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GLIOBLASTOMA; METABOLISM; METRONOMIC DRUG ADMINISTRATION; TUMOR CELL LINE;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; GLIOBLASTOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957709183     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0274-y     Document Type: Article

References (49)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-66.
3. Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, et al. Dosedense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol. 2004;15:161-71.
4. Nagasubramanian R, Dolan ME. Temozolomide: realizing the promise and potential. Curr Opin Oncol. 2003;15:412-8.
5. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93-108.
6. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108:49-56.
7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-8.
8. Lakka SS, Rao JS. Antiangiogenic therapy in brain tumors. Expert Rev Neurother. 2008;8:1457-73.
9. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-24.
10. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-86.
11. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-7.
12. Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004;64:3994-4000.
13. Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MK, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 2006;16:33-9.
14. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-7.
15. Kong DS, Lee JI, Kim WS, Son MJ, do Lim H, Kim ST, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006;16:1117-21.
16. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, et al. Phase II trial of lowdose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010;12:289-96.
17. Chen C, Xu T, Lu Y, Chen J, Wu S. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol. 2013;20:223-30.
18. Kerschbaumer J, Schmidt FA, Grams AE, Nowosielski M, Pinggera D, Brawanski KR, et al. Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. Anticancer Res. 2015;35:4955-60.
19. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W. Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol. 2006;163:645-53.
20. Kim YJ, Zhang D, Yang DC. Biosynthesis and biotechnological production of ginsenosides. Biotechnol Adv. 2015;33:717-35.
21. Zhang F, Li M, Wu X, Hu Y, Cao Y, Wang X, et al. 20 (S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Des Devel Ther. 2015;9:3969-87.
22. Shan X, Tian LL, Zhang YM, Wang XQ, Yan Q, Liu JW. Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-kappaB/p65 signaling pathway to promote melanoma cell death. Int J Oncol. 2015;47:701-9.
23. Wang L, Li X, Song YM, Wang B, Zhang FR, Yang R, et al. Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to gamma-radiation by targeting the nuclear factor-kappaB pathway. Mol Med Rep. 2015;12:609-14.
24. Lee YJ, Lee S, Ho JN, Byun SS, Hong SK, Lee SE, et al. Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatinresistant bladder tumor cell line. Oncol Rep. 2014;32:1803-8.
25. Kim DG, Jung KH, Lee DG, Yoon JH, Choi KS, Kwon SW, et al. 20 (S) - Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. Oncotarget. 2014;5:4438-51.
26. Kim SS, Seong S, Kim SY. Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells. Oncol Lett. 2014;7:1265-9.
27. Choi YJ, Lee HJ, Kang DW, Han IH, Choi BK, Cho WH. Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species. Oncol Rep. 2013;30:1362-70.
28. Sin S, Kim SY, Kim SS. Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells. Int J Oncol. 2012;41:1669-74.
29. Kobayashi N, Allen N, Clendenon NR, Ko LW. An improved rat brain-tumor model. J Neurosurg. 1980;53:808-15.
30. Gahramanov S, Muldoon LL, Li X, Neuwelt EA. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. Radiology. 2011;261:796-804.
31. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-11.
32. Kurzen H, Schmitt S, Naher H, Mohler T. Inhibition of angiogenesis by nontoxic doses of temozolomide. Anticancer Drugs. 2003;14:515-22.
33. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol. 2005;131:31-40.
34. Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, et al. The angiosuppressive effects of 20 (R) - ginsenoside Rg3. Biochem Pharmacol. 2006;72:437-45.
35. Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phytomedicine-ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem. 2009;16:2924-42.
36. Zeng D, Wang J, Kong P, Chang C, Li J, Li J. Ginsenoside Rg3 inhibits HIF-1alpha and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways. Int J Clin Exp Pathol. 2014;7:2172-8.
37. Kim JW, Jung SY, Kwon YH, Lee JH, Lee YM, Lee BY, et al. Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. Cancer Biol Ther. 2012;13:504-15.
38. Zhou B, Wang J, Yan Z. Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model. Onco Targets Ther. 2014;7:1945-54.
39. Ng WY, Yang MS. Effects of ginsenosides Re and Rg3 on intracellular redox state and cell proliferation in C6 glioma cells. Chin Med. 2008;3:8.
40. Yang LQ, Wang B, Gan H, Fu ST, Zhu XX, Wu ZN, et al. Enhanced oral bioavailability and anti-tumor effect of paclitaxel by 20 (s)-Ginsenoside Rg3 in vivo. Biopharm Drug Dispos. 2012;33:425-36.
41. Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL, et al. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer. 2009;9:250.
42. Jo MY, Kim YG, Kim Y, Lee SJ, Kim MH, Joo KM, et al. Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms. Mol Med Report. 2012;6:88-92.
43. Lu XY, Cao K, Li QY, Yuan ZC, Lu PS. The Synergistic Therapeutic Effect of Temozolomide and Hyperbaric Oxygen on Glioma U251 Cell Lines is Accompanied by Alterations in Vascular Endothelial Growth Factor and Multidrug Resistance-associated Protein-1 Levels. J Int Med Res. 2012;40:995-1004.
44. Di Nallo AM, Vidiri A, Marzi S, Mirri A, Fabi A, Carapella CM, et al. Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases. J Exp Clin Cancer Res. 2009;28:38.
45. Barajas Jr RF, Cha S. Benefits of dynamic susceptibility-weighted contrastenhanced perfusion MRI for glioma diagnosis and therapy. CNS Oncol. 2014;3:407-19.
46. Romano A, Rossi Espagnet MC, Calabria LF, Coppola V, Figa Talamanca L, Cipirani V, et al. Clinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours. Radiol Med. 2012;117:445-60.
47. Thomsen H, Steffensen E, Larsson EM. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas. Acta Radiol. 2012;53:95-101.
48. Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012;33:69-76.
49. Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, et al. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res. 2012;31:33.